Latest Insider Transactions at Galera Therapeutics, Inc. (GRTX)
This section provides a real-time view of insider transactions for Galera Therapeutics, Inc. (GRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Galera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Galera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 16
2024
|
Mel Sorensen President and CEO |
SELL
Open market or private sale
|
Direct |
67,015
-20.18%
|
$0
$0.07 P/Share
|
|
Feb 08
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.83%
|
$0
$0.17 P/Share
|
|
Feb 07
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
175,000
+1.09%
|
$0
$0.17 P/Share
|
|
Feb 06
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
25,000
+0.32%
|
$0
$0.2 P/Share
|
|
Feb 05
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
97,402
+1.25%
|
$0
$0.18 P/Share
|
|
Jan 30
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
335,000
+4.22%
|
$0
$0.18 P/Share
|
|
Jan 29
2024
|
Yair Schneid > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+2.02%
|
$0
$0.18 P/Share
|
|
Mar 16
2023
|
Mark Bachleda Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
11,000
+50.0%
|
$22,000
$2.25 P/Share
|
|
Mar 13
2023
|
Chris Degnan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.96 P/Share
|
|
Mar 10
2023
|
Mel Sorensen President and CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+23.15%
|
$100,000
$1.68 P/Share
|
|
Nov 21
2022
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.46%
|
$10,000
$1.07 P/Share
|
|
Sep 12
2022
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+9.24%
|
$10,000
$1.07 P/Share
|
|
Jul 18
2022
|
Lawrence M Alleva |
SELL
Bona fide gift
|
Direct |
4,000
-63.24%
|
-
|
|
Dec 17
2021
|
Robert A Beardsley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+18.49%
|
$20,000
$1.07 P/Share
|
|
Dec 17
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
20,000
+25.0%
|
$40,000
$2.74 P/Share
|
|
Sep 01
2021
|
Jon T Holmlund Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
47,756
-100.0%
|
$382,048
$8.47 P/Share
|
|
Sep 01
2021
|
Jon T Holmlund Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,756
+50.0%
|
$95,512
$2.43 P/Share
|
|
Jun 15
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+20.0%
|
$90,000
$9.13 P/Share
|
|
Jun 02
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$80,000
$8.65 P/Share
|
|
Jun 01
2021
|
Lawrence M Alleva |
BUY
Open market or private purchase
|
Indirect |
4,045
+50.0%
|
$32,360
$8.59 P/Share
|
|
Jun 01
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$80,000
$8.64 P/Share
|
|
May 28
2021
|
Linda West |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.64 P/Share
|
|
Mar 26
2021
|
Mel Sorensen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
217,015
+32.35%
|
$217,015
$1.11 P/Share
|
|
Feb 18
2021
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
500,000
-16.9%
|
$5,000,000
$10.58 P/Share
|
|
Nov 13
2020
|
Lawrence M Alleva |
BUY
Open market or private purchase
|
Direct |
2,325
+26.88%
|
$23,250
$10.22 P/Share
|
|
Nov 13
2020
|
Joel F. Sussman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$100,000
$10.32 P/Share
|
|
Nov 13
2020
|
Joel F. Sussman Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.89%
|
$10,000
$1.55 P/Share
|
|
Nov 12
2020
|
Joel F. Sussman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$100,000
$10.06 P/Share
|
|
Nov 12
2020
|
Joel F. Sussman Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$10,000
$1.07 P/Share
|
|
Oct 26
2020
|
Jon T Holmlund Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,244
-100.0%
|
$33,660
$15.0 P/Share
|
|
Oct 26
2020
|
Jon T Holmlund Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,244
+50.0%
|
$4,488
$2.43 P/Share
|
|
Oct 15
2020
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
450,000
-13.2%
|
$4,950,000
$11.0 P/Share
|
|
Oct 06
2020
|
Jon T Holmlund Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,536
-100.0%
|
$126,432
$12.0 P/Share
|
|
Oct 06
2020
|
Jon T Holmlund Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,536
+50.0%
|
$10,536
$1.11 P/Share
|
|
Oct 05
2020
|
Jon T Holmlund Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$1,200
$12.0 P/Share
|
|
Oct 05
2020
|
Jon T Holmlund Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$100
$1.07 P/Share
|
|
Jun 19
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
1,001,312
-28.86%
|
$8,010,496
$8.25 P/Share
|
|
Jun 18
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
900
-0.03%
|
$8,100
$9.04 P/Share
|
|
Jun 17
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
4,622
-0.13%
|
$41,598
$9.27 P/Share
|
|
Jun 16
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
8,600
-0.25%
|
$77,400
$9.3 P/Share
|
|
Jun 15
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
6,164
-0.18%
|
$55,476
$9.05 P/Share
|
|
Jun 12
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
1,500
-0.04%
|
$13,500
$9.19 P/Share
|
|
Jun 11
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
7,200
-0.21%
|
$64,800
$9.21 P/Share
|
|
Jun 10
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
8,532
-0.24%
|
$76,788
$9.46 P/Share
|
|
Jun 09
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
7,000
-0.2%
|
$63,000
$9.38 P/Share
|
|
Jun 08
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
5,659
-0.16%
|
$50,931
$9.66 P/Share
|
|
Jun 05
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
8,652
-0.25%
|
$77,868
$9.66 P/Share
|
|
Jun 04
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
4,088
-0.12%
|
$36,792
$9.55 P/Share
|
|
Jun 03
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
5,208
-0.15%
|
$46,872
$9.78 P/Share
|
|
Jun 02
2020
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
5,669
-0.16%
|
$51,021
$9.68 P/Share
|